We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+26.16%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$11.4B
AUM Growth
+$1.76B
(+18%)
Cap. Flow
-$330M
Cap. Flow
% of AUM
-2.89%
Top 10 Holdings %
Top 10 Hldgs %
18.38%
Holding
1,151
New
138
Increased
341
Reduced
503
Closed
146
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$32.1M |
| 2 |
Intel
INTC
|
+$28.7M |
| 3 |
Gilead Sciences
GILD
|
+$27.7M |
| 4 |
APA Corp
APA
|
+$27.5M |
| 5 |
Costco
COST
|
+$25.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OPTU
Optimum Communications Inc
OPTU
|
+$41M |
| 2 |
Align Technology
ALGN
|
+$38.9M |
| 3 |
Qualcomm
QCOM
|
+$33.6M |
| 4 |
H&R Block
HRB
|
+$31.8M |
| 5 |
CBRE Group
CBRE
|
+$28.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.64% |
| 2 | Healthcare | 14.08% |
| 3 | Consumer Discretionary | 13.88% |
| 4 | Financials | 13.05% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIOR
801
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
| $704K | 0.01% |
530
+422
| +391% | +$619K |
|
802
Precision BioSciences
DTIL
$178M
| $701K | 0.01% |
2,801
-2,071
| -43% | -$508K |
|
803
Itron
ITRI
$4.48B
| $696K | 0.01% |
7,255
-1,191
| -14% | -$91.6K |
|
804
Kiniksa Pharmaceuticals
KNSA
$6.31B
| $696K | 0.01% |
39,394
-2,386
| -6% | -$41.9K |
|
805
ABM Industries
ABM
$2.89B
| $692K | 0.01% |
+18,288
| New | +$693K |
|
|
WBA
806
DELISTED
Walgreens Boots Alliance
WBA
| $691K | 0.01% |
17,323
-100
| -0.6% | -$3.87K |
|
807
DHT Holdings
DHT
$2.99B
| $688K | 0.01% |
131,562
+38,023
| +41% | +$198K |
|
808
NextCure
NXTC
$20.4M
| $687K | 0.01% |
+5,252
| New | +$679K |
|
809
Customers Bancorp
CUBI
$2.66B
| $682K | 0.01% |
+37,537
| New | +$595K |
|
|
PCSB
810
DELISTED
PCSB Financial Corporation
PCSB
| $681K | 0.01% |
42,748
-5,646
| -12% | -$83.6K |
|
811
Xeris Biopharma Holdings
XERS
$1.45B
| $671K | 0.01% |
136,397
+100,946
| +285% | +$505K |
|
812
Waterstone Financial
WSBF
$371M
| $663K | 0.01% |
+35,225
| New | +$616K |
|
|
TRTN
813
DELISTED
Triton International Limited
TRTN
| $663K | 0.01% |
+13,671
| New | +$578K |
|
814
Shore Bancshares
SHBI
$820M
| $659K | 0.01% |
45,158
+2,414
| +6% | +$31K |
|
815
Karyopharm Therapeutics
KPTI
$155M
| $658K | 0.01% |
+2,835
| New | +$657K |
|
816
Johnson & Johnson
JNJ
$640B
| $636K | 0.01% |
4,044
-6,351
| -61% | -$937K |
|
|
OTIC
817
DELISTED
Otonomy, Inc.
OTIC
| $620K | 0.01% |
95,888
-11,766
| -11% | -$53.5K |
|
818
Cardlytics
CDLX
$22.2M
| $618K | 0.01% |
+433
| New | +$462K |
|
|
FARM
819
DELISTED
Farmer Brothers
FARM
| $614K | 0.01% |
131,374
+1,927
| +1% | +$8.26K |
|
|
HONE
820
DELISTED
HarborOne Bancorp
HONE
| $613K | 0.01% |
56,485
+2,033
| +4% | +$20K |
|
|
RRD
821
DELISTED
RR Donnelley & Sons Co.
RRD
| $613K | 0.01% |
+271,367
| New | +$408K |
|
822
Affiliated Managers Group
AMG
$9.51B
| $611K | 0.01% |
6,012
-15,315
| -72% | -$1.32M |
|
823
Neurocrine Biosciences
NBIX
$18.2B
| $605K | 0.01% |
6,308
-25,173
| -80% | -$2.43M |
|
824
Bridgewater Bancshares
BWB
$580M
| $603K | 0.01% |
48,271
+2,384
| +5% | +$27.6K |
|
825
Spok Holdings
SPOK
$229M
| $598K | 0.01% |
53,727
+13,487
| +34% | +$133K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2020 Portfolio in Review
As of Q4 2020, Jacobs Levy Equity Management held 1,151 positions worth $11.4B, up 18% from $9.65B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jacobs Levy Equity Management's Q4 2020 filing shows 138 new, 341 increased, 503 reduced and 146 closed positions. Its largest new stake was DexCom: 229,736 shares worth $21.2M. The largest sale was Optimum Communications Inc, an estimated $41M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q4 2020 buy was DexCom: 229,736 shares worth $21.2M.
- Jacobs Levy Equity Management added most to Amazon in Q4 2020, an estimated $32.1M increase.
- Jacobs Levy Equity Management's biggest Q4 2020 reduction was Qualcomm, cutting an estimated $33.6M.
- Jacobs Levy Equity Management fully exited Optimum Communications Inc in Q4 2020, selling an estimated $41M.
- Jacobs Levy Equity Management's ten largest holdings make up 18% of its $11.4B portfolio in Q4 2020.
- Jacobs Levy Equity Management opened 138 new positions and closed 146 in Q4 2020.
- Jacobs Levy Equity Management's portfolio value rose 18% quarter-over-quarter to $11.4B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.